David G Besselsen

David G Besselsen

Veterinary Specialist
Adjunct Associate Professor, Animal and Comparative Biomedical Sciences
Associate Research Scientist, BIO5 Institute
Member of the General Faculty
Member of the Graduate Faculty
Primary Department
Contact
(520) 626-6702

Research Interest

David Besselsen, DVM, PhD, is the Director of University Animal Care (UAC), the Attending Veterinarian. He is a board-certified veterinary specialist (Diplomate) in the American College of Laboratory Animal Medicine and the American College of Veterinary Pathology, and served as Interim Dean for the College of Veterinary Medicine from 2017-2019. In addition to his administrative and service responsibilities, Dr. Besselsen is actively engaged in research through the provision of comparative pathology support for rodent models and oversight of the gnotobiotic mouse service. He has directed UAC Pathology Services since his arrival in 1995 and has over 80 peer-reviewed publications. UAC Pathology Services provides diagnostic and comparative pathology support for the research animals and research animal facilities at the University of Arizona. Capabilities include hematology, blood chemistry, necropsy, histologic preparation and interpretation, and others.

Publications

Besselsen, D. G., Patil, K., Stokes, J., Hoffman, E., & Doane, C. J. (2017). Supernumary Incisors Associated with Administration of Chemotherapeutic Agents in CB6F1 Mice. JAALAS.
Ignatenko, N. A., Gerner, E. W., & Besselsen, D. G. (2011). Defining the role of polyamines in colon carcinogenesis using mouse models. Journal of carcinogenesis, 10.

Genetics and diet are both considered important risk determinants for colorectal cancer, a leading cause of death in the US and worldwide. Genetically engineered mouse (GEM) models have made a significant contribution to the characterization of colorectal cancer risk factors. Reliable, reproducible, and clinically relevant animal models help in the identification of the molecular events associated with disease progression and in the development of effictive treatment strategies. This review is focused on the use of mouse models for studying the role of polyamines in colon carcinogenesis. We describe how the available mouse models of colon cancer such as the multiple intestinal neoplasia (Min) mice and knockout genetic models facilitate understanding of the role of polyamines in colon carcinogenesis and help in the development of a rational strategy for colon cancer chemoprevention.

Hahn, T., Bradley-Dunlop, D. J., Hurley, L. H., Von-Hoff, D., Gately, S., Mary, D. L., Lu, H., Penichet, M. L., Besselsen, D. G., Cole, B. B., Meeuwsen, T., Walker, E., & Akporiaye, E. T. (2011). The vitamin E analog, alpha-tocopheryloxyacetic acid enhances the anti-tumor activity of trastuzumab against HER2/neu-expressing breast cancer. BMC cancer, 11.
BIO5 Collaborators
David G Besselsen, Laurence Hurley

HER2/neu is an oncogene that facilitates neoplastic transformation due to its ability to transduce growth signals in a ligand-independent manner, is over-expressed in 20-30% of human breast cancers correlating with aggressive disease and has been successfully targeted with trastuzumab (Herceptin®). Because trastuzumab alone achieves only a 15-30% response rate, it is now commonly combined with conventional chemotherapeutic drugs. While the combination of trastuzumab plus chemotherapy has greatly improved response rates and increased survival, these conventional chemotherapy drugs are frequently associated with gastrointestinal and cardiac toxicity, bone marrow and immune suppression. These drawbacks necessitate the development of new, less toxic drugs that can be combined with trastuzumab. Recently, we reported that orally administered alpha-tocopheryloxyacetic acid (α-TEA), a novel ether derivative of alpha-tocopherol, dramatically suppressed primary tumor growth and reduced the incidence of lung metastases both in a transplanted and a spontaneous mouse model of breast cancer without discernable toxicity.

Ball, C. L., Daniel, S. G., Besselsen, D. G., Hurwitz, B. L., & Doetschman, T. C. (2017). Functional changes in the gut microbiome contribute to Transforming Growth Factor β-deficient colon cancer. mSystems, 2(5), 1-17.
BIO5 Collaborators
David G Besselsen, Thomas C Doetschman, Bonnie L Hurwitz
McFadden, R. T., Larmonier, C. B., Shehab, K. W., Midura-Kiela, M., Ramalingam, R., Harrison, C. A., Besselsen, D. G., Chase, J. H., Caporaso, J. G., Jobin, C., Ghishan, F. K., & Kiela, P. R. (2015). The Role of Curcumin in Modulating Colonic Microbiota During Colitis and Colon Cancer Prevention. Inflammatory bowel diseases, 21(11), 2483-94.

Intestinal microbiota influences the progression of colitis-associated colorectal cancer. With diet being a key determinant of the gut microbial ecology, dietary interventions are an attractive avenue for the prevention of colitis-associated colorectal cancer. Curcumin is the most active constituent of the ground rhizome of the Curcuma longa plant, which has been demonstrated to have anti-inflammatory, antioxidative, and antiproliferative properties.